Skip to main content
OpenTrials
Completed

NCT Number: NCT04853147

Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal Surgery

Postoperative nausea and vomiting (PONV) are common in patients, especially in patients at high risk. PONV may result in prolonged hospital stay and threaten patients' life. Because the etiology of PONV is very complex, there is an increasing focus on combining antiemetics from different classes for PONV prophylaxis. Fosaprepitant is a neurokinin-1 (NK-1) receptor antagonist to prevent PONV. Palonosetron is a 5-HT3 receptor antagonist with high efficacy and sustained action for PONV prophylaxis. Dexamethasone belongs to corticosteroid and also has the ability to reduce the incident of PONV. This study aims to use the combination of these three drugs in high-risk patients to test whether triple therapy is better than combination of palonosetron and dexamethasone to prevent PONV.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

C.Surgical Procedure; Gastrointestinal Nausea Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Postoperative Nausea and Vomiting Signs and Symptoms Signs and Symptoms, Digestive Vomiting

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

The Sixth Affiliated Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510655, China

About this study

This trial is a prospective, randomized controlled study with blinded participant, care provider, investigator, and outcomes assessor. 1154 patients aged 18 to 75 years undergoing laparoscopic gastrointestinal surgery will be enrolled.Triple therapy of palonosetron and dexamethasone plus fosaprepitant will be administered in the intervention group, and double therapy of palonosetron and dexamethasone will be used in the control group. The anxiety of patients will be evaluated. The primary outcome is proportion of participants with PONV during the first 24 postoperative hours. Secondary outcomes are as follow: proportion of participants with PONV,emetic episodes, nausea, with rescue antiemetic medication; the scores of QOR-15; pain scores;time to first flatus after surgery; time to first defecation after surgery; recovery time; health related quality of life; proportion of participants with adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years and Age ≤75 years;
  • Scheduled for laparoscopic gastrointestinal surgical procedure with general anesthesia ;
  • The score evaluated by Apfel simplified PONV risk assessment systems is ≥3.

Exclusion criteria

  • The American Society of Anesthesiologists (ASA) rating is >3;
  • Severe hepatic dysfunction(the score of Child-Pugh is >9);
  • With contraindications for using fosaprepitant, 5-HT3 receptor antagonist or dexamethasone ;
  • Take medications with known antiemetic properties preoperatively ;
  • With mental disorder, or not be able to communicate ;
  • Pregnant women or nursing mothers.

Treatment and study plan

palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl

Drug

palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, fosaprepitant 150mg dissolved in 0.9% NaCl 150ml, iv.drip,

Other names: Triple therapy

palonosetron, dexamethasone, and 0.9% NaCl

Drug

palonosetron 0.075 mg, iv, dexamethasone 5mg, iv, 0.9% NaCl 150ml, iv.drip,

Other names: double therapy

Primary outcomes

  1. Proportion of participants with PONV during the first 24 postoperative hours

    Time frame: from operation completion to 24-hour after surgery (up to 24 hours)

    PONV is defined as nausea, retching or vomiting

Secondary outcomes

  1. Proportion of participants with PONV

    Time frame: calculated at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)

    PONV is defined as nausea, retching or vomiting

  2. Proportion of participants with emetic episodes

    Time frame: calculated at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)

    Emetic episodes are defined as retching or vomiting or both

  3. Proportion of participants with nausea

    Time frame: calculated at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)

    Nausea is defined as a feeling of the urge to vomit

  4. Proportion of participants with rescue antiemetic medication

    Time frame: calculated at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)

    Rescue antiemetic medication

  5. The severity of PONV

    Time frame: calculated at 24-hour, 72-hour, 120-hour after surgery(daily recorded up to 120 hours after surgery)

    The severity of PONV is evaluated by a PONV impact scale score. Nausea intensity is scored as 1 ,2 ,3. In addition, vomiting intensity is scored as the number of vomits (0-2, or 3 if three or more vomits). Both scores together to obtain the PONV impact scale score

  6. Postoperative recovery score using 15-item quality of recovery scoring system(QoR-15) during each subsequent evaluation period (up to 120 hours)

    Time frame: evaluated at 24-hour, 72-hour, 120-hour after surgery(up to 120 hours after surgery)

    The QoR-15 comprises five subscales: pain, physical comfort, physical independence, psychological support, and emotional state. Each item is scored from 0 to 10, and the possible total score ranges from 0 to 150. A higher total score means better patient QoR.

  7. Pain scores

    Time frame: evaluated at 24-hour, 72-hour, 120-hour after surgery(up to 120 hours after surgery)

    Pain scores are evaluated by numerical rating scale(NRS) from no pain(0) to most severe pain (10).

  8. Time to first flatus after surgery

    Time frame: evaluated at the time of first exhaust after surgery(expected average of 3 days after surgery)

    Time length between operation completion and the first flatus

  9. Time to first defecation after surgery

    Time frame: evaluated at the time of the first defecation after surgery(expected average of 6 days after surgery

    Time length between operation completion and the first defecation

  10. Time to fulfill the criteria of hospital discharge (recovery time)

    Time frame: from operation completion to fulfill the criteria of hospital discharge(expected 6 days )

    The ideal time point for discharge, which is also considered as recovery time.

  11. Health related quality of life

    Time frame: evaluated before surgery, at 120-hour and 30 days after surgery (up to 30 days）

    Health related quality of life is measured by EQ-5D. Each EQ-5D health state can be coded into a five-digit number using the numbers 1 , 2 , and 3 to indicate the functional levels of the five dimensions.

  12. Proportion of patients with adverse events (up to 30 days after surgery)

    Time frame: from drug administration to 30 days (30 days)

    adverse events

Other outcomes

  1. Concentration of materials in blood such as hormone and metabolic

    Time frame: evaluated before surgery, at the end of surgery

    materials in blood

  2. 6-month survival rate

    Time frame: 6-month after surgery

    survival rate in 6-month after surgery

Sponsors and collaborators

Lead sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Other

Registry information

Official study title

Triple Combination of Fosaprepitant, Dexamethasone and Palonosetron Versus Combination of Dexamethasone and Palonosetron for the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gastrointestinal Surgery

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 21, 2021
Registry last updated
Dec 29, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.